When does VYNDaqel’s patent expire?
VYNDaqel (tafamidis) patent expiration timing depends on the specific patent(s) covering the drug and the country. Patent terms also may be extended by mechanisms like patent term adjustments/extensions and exclusivity rules, so “the” go‑off date is not a single fixed year across jurisdictions.
Can it lose exclusivity before all patents expire?
Yes. Even if some patents remain in force, regulators and courts can allow certain competitors to enter earlier via:
- Patent cliffs (when the most important composition/patent claims expire)
- Regulatory exclusivity periods expiring (separate from patents)
- Challenges that narrow or invalidate specific patents
What matters for generics or biosimilars timing?
For small-molecule drugs like tafamidis, generic entry timing typically turns on when the relevant formulation/composition and method patents expire and whether any additional hurdles (like patent litigation stay orders) delay approval.
How to find the exact “go‑off patent” date you need
To get the correct date, you’d need:
- The country/market (US, EU, UK, etc.)
- The exact strength/formulation (if different patents cover different products)
- The specific patent numbers listed in local patent linkage systems
If you tell me which country you mean (for example, US vs EU), I can narrow the answer to the applicable patent/exclusivity framework for that market.